<DOC>
	<DOC>NCT00821444</DOC>
	<brief_summary>Commercial ziprasidone capsules show a large increase in bioavailability with food. The formulation tested in this study aims to reduce or eliminate that increase.</brief_summary>
	<brief_title>Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules</brief_title>
	<detailed_description />
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Healthy subjects Signed informed consent document Any significant physical or psychological disease Concomitant administration of other pharmaceuticals</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>schizophrenia, pharmacokinetics, bioavailability, food effect</keyword>
</DOC>